The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ELV | -17.99% | +27.97% | +5.06% | +1,985% |
| S&P | +18.37% | +110.18% | +16.02% | +549% |
Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Commercial and Specialty Business, Government Business, CarelonRx, and Other. The Commercial and Specialty Business segment provides insurance products and services such as stop loss, dental, vision, life, disability and supplemental health insurance. The Government Business segment includes medicare and medicaid businesses, national government services, and services provided to the federal government. The CerelonRx segment offers formulary management, pharmacy networks, prescription drug database, member services, and mail order capabilities. The Other segment is involved in health services business focused on quality of healthcare by enabling and creating new care delivery and payment models. The company was founded in 1944 and is headquartered in Indianapolis, IN.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $50.71B | 12.3% |
| Market Cap | $72.76B | -39.7% |
| Market Cap / Employee | $0.70M | 0.0% |
| Employees | 104.2K | -0.7% |
| Net Income | $1.19B | 17.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $8.71B | 10.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $31.17B | 26.3% |
| Short Term Debt | $929.00M | -62.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 4.62% | -1.0% |
| Return On Invested Capital | 9.37% | -0.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $775.00M | -67.0% |
| Operating Free Cash Flow | $1.14B | -57.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 14.40 | 16.97 | 16.56 | 13.21 | -30.28% |
| Price to Book | 1.95 | 2.39 | 2.06 | 1.66 | -41.87% |
| Price to Sales | 0.48 | 0.54 | 0.46 | 0.37 | -46.74% |
| Price to Tangible Book Value | 11.43 | 104.81 | 40.95 | 18.80 | -9.85% |
| Price to Free Cash Flow TTM | 28.01 | 45.77 | 23.02 | 32.24 | -76.82% |
| Free Cash Flow Yield | 3.6% | 2.2% | 4.3% | 3.1% | 331.48% |
| Return on Equity | 14.8% | 14.2% | 12.5% | 12.6% | -19.22% |
| Total Debt | $32.04B | $30.00B | $30.19B | $32.10B | 18.25% |
ELV earnings call for the period ending December 31, 2024.
ELV earnings call for the period ending September 30, 2024.
ELV earnings call for the period ending June 30, 2024.
ELV earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
